Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ...
Science Daily

Hidden weakness makes prostate cancer self-destruct

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.
Stars Insider on MSN

Blood test cuts prostate cancer death risk by 13%, according to large European study

A decades-long European study, published in the New England Journal of Medicine, has found that screening men for ...

Breakthrough breathalyzer test can quickly screen for lung cancer — here’s how it works

Researchers have developed a groundbreaking device that may one day make detecting lung cancer as easy as exhaling. “We built ...

Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets artificial intelligence (“AI”)-powered, MRI-guided, ...
Becker's Hospital Review

How agentic AI is reshaping clinical workflows: 4 takeaways

Agentic AI reshaping clinical workflows improves productivity, automates tasks, and enhances governance in health systems, says Dr. Tom Kelly of Heidi.

Profound Medical Reports Strong Third Quarter 2025 Financial Results

Revenue grew 87% year-over-year to a record $5.3 million in the third quarter of 2025. Gross margin increased 1,119 basis points year-over-year to 74.3% in Q3-2025. The Company’s TULSA-PRO ® qualified ...

Profound Medical Corp.: Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered ...

A simple blood test can detect 50 types of cancer: We explain

The Galleri test, by American company GRAIL, can detect over 50 types of cancerous DNA with a simple blood test. How the cancer screening test works.

AI in Oncology Market Size to Accumulate Around USD 27.17 Billion by 2032 as Precision Medicine and AI Diagnostics Reshape Cancer Care – SNS Insider

Surging cancer prevalence, expanding AI-powered diagnostics, and major healthcare digitalization initiatives accelerate the global AI in oncology market growth at a CAGR of 26.23% through 2032.Austin, ...

Dr. Roach: Rising PSA level prompts questions about next steps

I do not recommend stopping aspirin without discussing with your doctor. I do not recommend stopping aspirin without discussing with your doctor. I do not recommend stopping aspirin without discussing ...
Urology Care Foundation

New Guide Helps Patients Navigate Genetic Testing for Advanced Prostate Cancer

BALTIMORE, Nov. 13, 2025 (GLOBAL NEWSWIRE) — The Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), and the Prostate Cancer Foundation (PCF) today ...